"Actionnable"..... "competitive landscape" the sentence that really bothers me is the one they used in the Feb press release:
"We will, over the next few months, work closely with the FDA, our advisors and our development partners to analyze the clinical and regulatory path forward in the United States and Europe, as well as the current competitive landscape and the costs and timelines to conduct a second Phase 3 trial .
what "competitive landscape" do you have to look at? You have a single product that you argued is the second line cure to bladder cancer, back in november. What happened in those 3 months betwenn nov and feb that warrant such an analysis?